Home » Topics » BioWorld Science

BioWorld Science
RSS

ALG-1007 study meets all primary and secondary endpoints

Aug. 4, 2021

Telmisartan reduces morbidity and mortality in hospitalized patients with COVID-19

Aug. 4, 2021

Serum miRNA451a levels are increased in Alzheimer's disease patients

Aug. 4, 2021

ALZ-201 neutralizes the neurotoxicity of postmortem brain extracts from patients with AD

Aug. 4, 2021

Disarm Therapeutics discovers NAD(+) hydrolase SARM1 inhibitors

Aug. 4, 2021

Bristol Myers Squibb patents CD80/PD-L1 and/or PD-1/PD-L1 interaction inhibitors

Aug. 4, 2021

New PD-1/PD-L1 interaction inhibitors synthesized at Abbisko Therapeutics

Aug. 4, 2021

CytomX Therapeutics describes auristatin-related compounds

Aug. 4, 2021

First patient dosed in a phase I study of ARX-517

Aug. 4, 2021

Antibe places its AME study of otenaproxesul on required pause

Aug. 4, 2021

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...